Kelly Taft
Family · Montrose, MINPI 1447536479
Payments from drug & device makers
Across 226 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$579
- Novo Nordisk$544
- Otsuka America Pharmaceutical, Inc.$277
- AstraZeneca$254
- Vanda Pharmaceuticals Inc.$240
- Lundbeck LLC$237
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $579 |
| Novo Nordisk | 35 | $544 |
| Otsuka America Pharmaceutical, Inc. | 17 | $277 |
| AstraZeneca(2 entities) | 16 | $254 |
| Vanda Pharmaceuticals Inc. | 11 | $240 |
| Lundbeck LLC | 12 | $237 |
| Lilly USA, LLC | 14 | $233 |
| GSK | 12 | $198 |
| Novartis | 7 | $185 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $173 |
| Harmony Biosciences LLC | 5 | $126 |
| Pfizer | 8 | $121 |
| Boston Scientific | 1 | $119 |
| UCB, Inc. | 6 | $111 |
| Exact Sciences | 4 | $74 |
| Acadia Pharmaceuticals Inc | 3 | $72 |
| Neurelis, Inc. | 5 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Biohaven Pharmaceuticals, Inc. | 1 | $48 |
| Biogen | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Bayer | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Amgen | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Abiomed | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Abbott | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$204
- EXALT Model D$119
- QULIPTA$104
How this compares
$4,203 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $163,543 |
| MounjaroTirzepatide | 91 | $133,532 |
| EliquisApixaban | 147 | $131,782 |
| RexultiBrexpiprazole | 34 | $81,613 |
| TrulicityDulaglutide | 48 | $63,000 |
| LinzessLinaclotide | 60 | $49,235 |
| JardianceEmpagliflozin | 48 | $48,860 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $47,791 |
| JanuviaSitagliptin Phosphate | 52 | $45,405 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $33,007 |
| Repatha SureclickEvolocumab | 32 | $25,209 |
| RybelsusSemaglutide | 15 | $24,682 |
| XareltoRivaroxaban | 22 | $21,383 |
| EntrestoSacubitril/Valsartan | 20 | $17,865 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $9,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $233 | $196,532139 claims |
| Novo NordiskOzempic, Rybelsus | $544 | $188,225117 claims |
| PfizerEliquis | $121 | $131,782147 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $277 | $81,61334 claims |
| AbbVieLinzess | $579 | $49,23560 claims |
| Boehringer IngelheimJardiance | $22 | $48,86048 claims |
| GSKTrelegy Ellipta | $198 | $47,79164 claims |
| AstraZenecaBreztri Aerosphere, Brilinta | $254 | $42,12763 claims |
| NovartisEntresto | $185 | $17,86520 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $6,90912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.
Other family in Montrose
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.